Ultra-Widefield Fluorescein Angiography to Monitor Therapeutic Response to Adalimumab in Behcet’s Uveitis

ABSTRACT

Purpose

To investigate the role of ultra-widefield fluorescein angiography (UWFA) for monitoring therapeutic response to adalimumab in patients with Behcet’s uveitis.

Methods

Patients with Behcet’s uveitis treated with adalimumab for ≥30 weeks were included. Intraocular inflammation, best-corrected visual acuity, systemic medications, and UWFA scores were evaluated.

Results

Thirty-eight eyes of 20 patients were included. Significant decreases in grading of anterior chamber cells and vitreous haze were observed at 6, 14, and 30 weeks after adalimumab administration (p < .001 for all). UWFA scores on vascular and capillary leakage were decreased at week 6 and further improved at weeks 14 and 30. Moreover, UWFA score further decreased at 14 and 30 weeks, even after manifest inflammation became quiescent at 6 weeks. (p = .004 and 0.001, respectively).

Conclusion

UWFA scores significantly improved in Behcet’s uveitis patients treated with adalimumab, and further improvement of UWFA scores was found in patients with a clinically quiescent inflammatory state.

KEYWORDS:

• Ultra-widefield fluorescein angiography
• adalimumab
• Behcet’s disease
• retinal vasculitis
• uveitis

Declaration of interest

The authors report no conflicts of interest. The authors have no proprietary or commercial interests in any of the materials discussed in this article and are not supported by any financial support funding. The authors are responsible for the content and writing of the paper.